The GLF is a scientific meeting sponsored by Genzyme that brings together approximately 200 participants from around the world, including physicians, academics, researchers and patient organization representatives to discuss current care for patients with Gaucher disease and the direction of future disease management. This year’s GLF will be chaired by Timothy M. Cox, Professor of Medicine at the University of Cambridge. The theme for 2015 is: “New Clinical Science of Gaucher Disease” and will focus on the following objectives:
- Advancing therapeutics through greater understanding of pathogenesis (molecular & otherwise)
- Fostering collaborative and interdisciplinary research
- Inspiring (recruiting) the next generation of clinician researchers and scientists
“In designing this year’s GLF program, we have sought to encompass the hugely diverse aspects of Gaucher disease as they impinge on the lives and well-being of patients all over the world. It is chastening to realize that despite radical improvements over the last 25 years, many aspects of this condition remain very hard to treat; and even when the diagnosis eventually has come to light, not every patient can gain access to the best standards of care,” said Prof. Cox. “This meeting will give time for open sharing of experience and seeks to explore under-recognized aspects of the disease that are often neglected in the heat of routine practice.”
The opening plenary session will highlight the most recent scientific discoveries in the field of Gaucher disease research. Additionally, several interactive working groups have been established to focus on: (1) Spectrum of Clinical Manifestations in Gaucher Disease; (2) Gaucher Disease Type 3: Addressing Patients’ and Families’ Concerns; (3) Unmet Needs in the Assessment of Bone Disease in Gaucher; and (4) Gaucher Disease and Cancer: Mechanisms and Management.
“The GLF is an excellent example of global collaboration and partnership, with the Gaucher community working together to propel research forward and further our understanding of Gaucher disease,” said Genzyme’s Acting Head of Rare Diseases, Richard Peters, MD, Ph.D. “While much progress has been made, great need still exists, particularly around the neuronopathic forms of Gaucher disease. We look forward to lively discussion while we work to achieve our collective goal to support the needs of the global Gaucher community.”
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.